AB
Aline Betancourt
CEO
Vitabolus, Inc
I'm working on
5 months ago
Breakthrough platform technology to orally deliver cell therapy
About
The proprietary alginate based hydrogel technology has achieved proof of concept and FDA pre-IND consultation to deploy anti-inflammatory cells to the gut for treatment of inflammatory bowel disease. Privately held, grant funded start-up seeking series A.
Partnering listings
Learn more
Vitabolus, Inc
Alginate-based encapsulation technology for enhanced product stability
Vitabolus, Inc. presents an alginate-based encapsulation technology designed to enhance the stability and safety of various products. Utilizing naturally derived alginate hydrogels, this solution is cost-effective and re...
TechnologyIn developmentCompany
Vitabolus, Inc
Alginate-based encapsulation for targeted probiotic delivery
This innovative solution utilizes alginate beads to encapsulate probiotics, ensuring their protection and targeted deployment to the intestines and colon. The technology supports room temperature storage and stability in...
TechnologyIn developmentCompany
No publications yet
This innovator hasn't added publications yet. In the meantime, you might want to explore their patents, funding, and other profile details.
The First Orally Delivered Cell Therapy for the Treatment of Inflammatory Bowel Disease
California Institute for Regenerative Medicine (CIRM)
•$250,000
•2021 - 2022
Formulations for non-parenteral administration of exosomes
Non-provisional
•2021
Oral delivery of therapeutic mammalian cells
Issued
•2019
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.